title: The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value.
abstract: The recently described oncogene ZNF217 belongs to a chromosomal region that is frequently amplified in human cancers. Recent findings have revealed that alternative mechanisms such as epigenetic regulation also govern the expression of the encoded ZNF217 protein. Newly discovered molecular functions of ZNF217 indicate that it orchestrates complex intracellular circuits as a new key regulator of tumorigenesis. In this review, we focus on recent research on ZNF217-driven molecular functions in human cancers, revisiting major hallmarks of cancer and highlighting the downstream molecular targets and signaling pathways of ZNF217. We also discuss the exciting translational medicine investigating ZNF217 expression levels as a new powerful biomarker, and ZNF217 as a candidate target for future anti-cancer therapies.
authors.affiliation: ISPB, Faculté de Pharmacie, Lyon, France.|Université Lyon 1, Lyon, France.|INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
authors.forename: Pascale A
authors.initials: PA
authors.lastname: Cohen
authors.affiliation: ISPB, Faculté de Pharmacie, Lyon, France.|Université Lyon 1, Lyon, France.|INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
authors.forename: Caterina F
authors.initials: CF
authors.lastname: Donini
authors.affiliation: ISPB, Faculté de Pharmacie, Lyon, France.|Université Lyon 1, Lyon, France.|INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
authors.forename: Nhan T
authors.initials: NT
authors.lastname: Nguyen
authors.affiliation: ISPB, Faculté de Pharmacie, Lyon, France.|Université Lyon 1, Lyon, France.|INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
authors.forename: Hubert
authors.initials: H
authors.lastname: Lincet
authors.affiliation: ISPB, Faculté de Pharmacie, Lyon, France.|Université Lyon 1, Lyon, France.|INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
authors.forename: Julie A
authors.initials: JA
authors.lastname: Vendrell
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D063646:Carcinogenesis / Q000187:drug effects / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002454:Cell Differentiation; D002465:Cell Movement; D049109:Cell Proliferation; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D058990:Molecular Targeted Therapy; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D012263:Ribonucleosides / Q000627:therapeutic use; D015398:Signal Transduction; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D012263:Ribonucleosides; D015534:Trans-Activators; C113698:ZNF217 protein, human; C023764:triciribine
keywords: ZNF217; biomarker; carcinogenesis; hallmarks of cancer; oncogene